CA2925939C - Substituted tetracycline compounds - Google Patents

Substituted tetracycline compounds Download PDF

Info

Publication number
CA2925939C
CA2925939C CA2925939A CA2925939A CA2925939C CA 2925939 C CA2925939 C CA 2925939C CA 2925939 A CA2925939 A CA 2925939A CA 2925939 A CA2925939 A CA 2925939A CA 2925939 C CA2925939 C CA 2925939C
Authority
CA
Canada
Prior art keywords
compound
hydrogen
pharmaceutically acceptable
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2925939A
Other languages
English (en)
French (fr)
Other versions
CA2925939A1 (en
Inventor
Paul Abato
Haregewein Assefa
Joel Berniac
Todd Bowser
Mark Grier
Laura Honeyman
Mohamed Ismail
Oak K. Kim
Mark Nelson
Jingwen Pan
Atul Verma
Beena Bhatia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
Original Assignee
Paratek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc filed Critical Paratek Pharmaceuticals Inc
Priority to CA3051994A priority Critical patent/CA3051994A1/en
Publication of CA2925939A1 publication Critical patent/CA2925939A1/en
Application granted granted Critical
Publication of CA2925939C publication Critical patent/CA2925939C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Indole Compounds (AREA)
CA2925939A 2006-12-21 2007-12-21 Substituted tetracycline compounds Active CA2925939C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3051994A CA3051994A1 (en) 2006-12-21 2007-12-21 Substituted tetracycline compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87631306P 2006-12-21 2006-12-21
US60/876,313 2006-12-21
US94300307P 2007-06-08 2007-06-08
US60/943,003 2007-06-08
CA2673466A CA2673466C (en) 2006-12-21 2007-12-21 Substituted tetracycline compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2673466A Division CA2673466C (en) 2006-12-21 2007-12-21 Substituted tetracycline compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3051994A Division CA3051994A1 (en) 2006-12-21 2007-12-21 Substituted tetracycline compounds

Publications (2)

Publication Number Publication Date
CA2925939A1 CA2925939A1 (en) 2008-07-03
CA2925939C true CA2925939C (en) 2019-10-01

Family

ID=39495878

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2673466A Active CA2673466C (en) 2006-12-21 2007-12-21 Substituted tetracycline compounds
CA3051994A Abandoned CA3051994A1 (en) 2006-12-21 2007-12-21 Substituted tetracycline compounds
CA2925939A Active CA2925939C (en) 2006-12-21 2007-12-21 Substituted tetracycline compounds

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA2673466A Active CA2673466C (en) 2006-12-21 2007-12-21 Substituted tetracycline compounds
CA3051994A Abandoned CA3051994A1 (en) 2006-12-21 2007-12-21 Substituted tetracycline compounds

Country Status (15)

Country Link
US (4) US8318706B2 (enExample)
EP (6) EP2450347B1 (enExample)
JP (8) JP5583411B2 (enExample)
KR (1) KR101538175B1 (enExample)
AU (1) AU2007338747B2 (enExample)
BR (1) BRPI0720569B8 (enExample)
CA (3) CA2673466C (enExample)
DK (1) DK2109602T3 (enExample)
ES (2) ES2463457T3 (enExample)
IL (4) IL270446B2 (enExample)
MX (1) MX2009006846A (enExample)
PL (1) PL2109602T3 (enExample)
PT (1) PT2109602E (enExample)
SI (1) SI2109602T1 (enExample)
WO (1) WO2008079339A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP2301912A3 (en) 2004-10-25 2012-07-11 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP1848685A1 (en) 2005-02-04 2007-10-31 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
ES2701725T3 (es) 2006-12-21 2019-02-25 Paratek Pharm Innc Compuestos de tetraciclina sustituida para el tratamiento de trastornos inflamatorios de la piel
ES2463457T3 (es) * 2006-12-21 2014-05-28 Paratek Pharmaceuticals, Inc. Derivados de la tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias
EP2176216B1 (en) * 2007-07-06 2012-04-25 Paratek Pharmaceuticals, Inc. Methods for synthesizing 9-substituted minocycline
US20090253660A1 (en) 2008-03-05 2009-10-08 Paratek Pharmaceuticals, Inc. Minocycline Compounds and Methods of Use Thereof
US20100022483A1 (en) * 2008-04-14 2010-01-28 Paratek Pharmaceuticals, Inc. Substituted Tetracycline Compounds
EP2341771A4 (en) * 2008-09-19 2012-08-15 Paratek Pharm Innc TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED THERAPEUTIC METHODS
CA2761241C (en) 2009-05-08 2018-02-27 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
WO2011025982A2 (en) * 2009-08-28 2011-03-03 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US8754054B2 (en) * 2010-07-09 2014-06-17 Albany Molecular Research, Inc. Antibacterial compounds, methods of making them, and uses thereof
US9255068B2 (en) * 2011-05-12 2016-02-09 Warner Chilcott Company, Llc Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
PL2738156T3 (pl) * 2011-07-26 2018-06-29 Kbp Biosciences Usa Inc. Związki tetracyklinowe podstawione 9-aminometylem
WO2013072703A1 (en) * 2011-11-18 2013-05-23 Redx Pharma Limited Antibacterial drug derivatives
CN103387512B (zh) * 2012-05-08 2016-08-31 成都睿智化学研究有限公司 一种米诺环素的制备方法及其中间体
US20130302442A1 (en) * 2012-05-14 2013-11-14 Paratek Pharmaceuticals, Inc. Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
CA2874640A1 (en) * 2012-05-30 2013-12-05 Paratek Pharmaceuticals, Inc. 7-disubstituted-phenyl tetracycline derivatives
US20150174144A1 (en) * 2012-07-13 2015-06-25 Paratek Pharmaceuticals, Inc. Tetracycline compounds for treating neurodegenerative disorders
DK2890673T3 (en) 2012-08-31 2019-03-18 Tetraphase Pharmaceuticals Inc tetracycline
JP2016089002A (ja) * 2014-10-31 2016-05-23 出光興産株式会社 ベンゾフラノチオフェン骨格を有するモノマー及びポリマー、及びそのポリマーを用いた有機薄膜太陽電池材料
DE102015013086A1 (de) 2015-10-01 2017-04-06 Jutta Regina Giller Attika für Gebäude
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations
DK3529236T3 (da) 2016-10-19 2024-05-13 Tetraphase Pharmaceuticals Inc Krystalformer af eravacyclin
MX2019005070A (es) 2016-11-01 2019-09-23 Paratek Pharm Innc Compuestos de 9-aminometil minociclina y su uso en el tratamiento de neumonía bacteriana adquirida en la comunidad (cabp).
EP3654988B1 (en) 2017-07-21 2023-09-06 Almirall, LLC Sarecycline for the treatment of non-inflammatory acne lesions
KR102011721B1 (ko) * 2017-11-28 2019-08-19 고려대학교 산학협력단 포도상구균의 생육을 억제하는 한천 유래 올리고당의 용도
US12297161B2 (en) 2018-04-06 2025-05-13 Almirall, Llc Process for making sarecycline hydrochloride
CN109970590A (zh) * 2018-12-20 2019-07-05 深圳市祥根生物科技有限公司 一种7-氨基米诺环素的制备方法
CN109574868B (zh) * 2018-12-28 2021-11-16 天津阿尔塔科技有限公司 一种四环素类及其差向异构体氘代内标物的制备方法
US20230181027A1 (en) * 2019-06-28 2023-06-15 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
WO2021231314A1 (en) * 2020-05-11 2021-11-18 Paratek Pharmaceuticals Inc. Methods of treating covid-19 using tetracycline compounds
CN111574392A (zh) * 2020-05-27 2020-08-25 浙江工业大学 一种6-去甲基-6-脱水四环素的制备方法
WO2025175063A1 (en) * 2024-02-14 2025-08-21 Cyclone Therapeutics, Inc. Tetracycline derivatives, and uses thereof

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34656A (en) 1862-03-11 Improvement in liquids for exciting galvanic batteries
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3047617A (en) * 1959-05-18 1962-07-31 Pfizer & Co C Alkanoic acid esters of 5-hydroxytetracycline and process for preparation
FR1003M (fr) 1960-03-09 1961-12-18 Erba Carlo Spa Dérivés d'antibiotiques a base de tétracycline.
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
GB1108310A (en) 1964-04-30 1968-04-03 Pfizer & Co C Derivatives of 6-methylene-tetracycline and process for their preparation
US3345379A (en) * 1965-02-26 1967-10-03 American Cyanamid Co 7-imidomethyl-6-demethyl-6-deoxytetracyclines
US3454697A (en) * 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
NL6607516A (enExample) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
NL158172B (nl) 1972-09-18 1978-10-16 Farmaceutici Italia Werkwijze voor het bereiden van tetracyclinederivaten met een substituent op de 7-plaats.
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
JPS5119757A (ja) 1974-06-25 1976-02-17 Farmaceutici Italia Arukirutetorasaikurinjudotainoseizoho
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US5064821A (en) * 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
US5589470A (en) * 1990-02-26 1996-12-31 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US4806529A (en) * 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4806372A (en) * 1985-02-15 1989-02-21 Georgia Oil & Gas Co., Inc. Nitrite-free-curing of bacon and product thereof
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
DE4042402C1 (enExample) 1990-10-03 1992-09-03 Degussa Ag, 6000 Frankfurt, De
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
US6756365B2 (en) * 1991-11-06 2004-06-29 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
DK0599397T3 (da) 1992-11-17 1996-09-16 Univ New York State Res Found Tetracycliner, herunder non-mikrobielle, kemisk-modificerede tetracycliner, inhiberer overdreven collagentværbinding ved diabetes
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
AU1279095A (en) 1994-02-17 1995-09-04 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
CA2219277A1 (en) 1995-05-03 1996-11-07 Pfizer Limited Novel tetracycline derivatives
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) * 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
IL137445A0 (en) * 1998-01-23 2001-07-24 Tufts College Pharmaceutically active compounds and methods of use thereof
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6256365B1 (en) * 1999-08-16 2001-07-03 Analogic Corporation Apparatus and method for reconstruction of images in a computed tomography system using oblique slices
US6849615B2 (en) * 1999-09-14 2005-02-01 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6500812B2 (en) 1999-09-14 2002-12-31 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
CZ301835B6 (cs) * 1999-09-14 2010-07-07 Trustees Of Tufts College Zpusob prípravy 7-, 9- nebo 13- substituované tetracyklinové slouceniny, reaktivní tetracyklinový chemický komplex a tetracyklinová sloucenina substituovaná v poloze 7 nebo 9
US6231894B1 (en) * 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
CA2397863A1 (en) * 2000-01-24 2001-07-26 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
KR20030007489A (ko) * 2000-03-31 2003-01-23 트러스티즈 오브 터프츠 칼리지 7- 및 9-카르바메이트, 우레아, 티오우레아,티오카르바메이트 및 헤테로아릴-아미노 치환된테트라사이클린 화합물
EP2308863A1 (en) * 2000-05-15 2011-04-13 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
US6706689B2 (en) 2000-05-19 2004-03-16 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with GLP-1
US20020132798A1 (en) * 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20040224927A1 (en) * 2000-06-16 2004-11-11 Trustees Of Tufts College 7-N-substituted phenyl tetracycline compounds
AU2001268475A1 (en) 2000-06-16 2002-01-02 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
US20050143353A1 (en) * 2000-07-07 2005-06-30 Paratek Pharmaceuticals, Inc. 13-Substituted methacycline compounds
US7094806B2 (en) * 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
CN1690047B (zh) 2000-07-07 2010-10-06 塔夫茨大学信托人 9-取代的二甲胺四环素化合物
JP4963771B2 (ja) * 2000-07-07 2012-06-27 トラスティーズ・オブ・タフツ・カレッジ ７、８および９−置換テトラサイクリン化合物
CN102336679A (zh) * 2000-07-07 2012-02-01 塔夫茨大学信托人 7-取代的四环素化合物
EA201000388A1 (ru) * 2001-03-13 2010-10-29 Пэрэтек Фамэсьютикэлс, Инк. Замещенные соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния субъекта
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
WO2002072506A2 (en) 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
EP1241160A1 (en) * 2001-03-13 2002-09-18 Glaxo Group Limited Tetracycline derivatives and their use as antibiotic agents
US6841546B2 (en) * 2001-03-14 2005-01-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as antifungal agents
EP1381372A2 (en) * 2001-03-14 2004-01-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
EP2186793A1 (en) * 2001-04-24 2010-05-19 Paratek Pharmaceuticals, Inc. Substituted Tetracycline Compounds
US8088820B2 (en) * 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2301550A1 (en) 2001-07-13 2011-03-30 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
AU2002365120A1 (en) * 2001-08-02 2003-07-15 Paratek Pharmaceuticals, Inc. Medicaments
WO2003023568A2 (en) * 2001-09-10 2003-03-20 Paratek Pharmaceuticals, Inc. Computational method for determining oral bioavailability
EP2311799A1 (en) * 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
EA201000491A1 (ru) * 2002-03-08 2010-08-30 Паратек Фармасьютикалс, Инк. Аминометилзамещенные тетрациклиновые соединения
AU2003218243B2 (en) * 2002-03-21 2010-04-01 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2476792A1 (en) 2002-04-16 2003-10-30 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
EA012136B1 (ru) 2002-07-12 2009-08-28 Пэрэтек Фамэсьютикэлс, Инк. Замещенные соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
CA2502464A1 (en) * 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
JP4686189B2 (ja) * 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Ｒｎａを調節するための置換テトラサイクリン化合物の使用方法
WO2004064728A2 (en) * 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
WO2004091513A2 (en) 2003-04-10 2004-10-28 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
JP4738333B2 (ja) * 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
US20060287283A1 (en) 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
KR101228706B1 (ko) * 2003-07-09 2013-02-01 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
US7786099B2 (en) * 2004-01-15 2010-08-31 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
WO2005082860A1 (en) * 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines and their use as calpain inhibitors
PL1753713T3 (pl) * 2004-05-21 2017-02-28 President And Fellows Of Harvard College Synteza tetracyklin oraz ich analogów
EP2301912A3 (en) * 2004-10-25 2012-07-11 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2284152A3 (en) * 2004-10-25 2011-10-05 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP1848685A1 (en) 2005-02-04 2007-10-31 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
US20070015738A1 (en) * 2005-07-15 2007-01-18 Walker Stephen G Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells
WO2007014154A2 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
AU2007208214B2 (en) * 2006-01-24 2013-02-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
AU2007249695A1 (en) * 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
ES2463457T3 (es) * 2006-12-21 2014-05-28 Paratek Pharmaceuticals, Inc. Derivados de la tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias
EP2144614A1 (en) * 2007-04-12 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
JP2010525069A (ja) 2007-04-27 2010-07-22 パラテック ファーマシューティカルズ インコーポレイテッド アミノアルキルテトラサイクリン化合物の合成方法および精製方法
EP2176216B1 (en) * 2007-07-06 2012-04-25 Paratek Pharmaceuticals, Inc. Methods for synthesizing 9-substituted minocycline
EP2341771A4 (en) * 2008-09-19 2012-08-15 Paratek Pharm Innc TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED THERAPEUTIC METHODS

Also Published As

Publication number Publication date
CA2925939A1 (en) 2008-07-03
IL270446A (enExample) 2019-12-31
AU2007338747A1 (en) 2008-07-03
EP2455367A1 (en) 2012-05-23
KR20090098986A (ko) 2009-09-18
US9012433B2 (en) 2015-04-21
US20210395189A1 (en) 2021-12-23
JP5583411B2 (ja) 2014-09-03
IL270446B1 (en) 2023-06-01
DK2109602T3 (da) 2014-05-19
EP3812372A3 (en) 2021-06-30
IL234755A (en) 2017-03-30
IL270446B2 (en) 2023-10-01
AU2007338747B2 (en) 2013-12-19
JP2014167027A (ja) 2014-09-11
US20130102779A1 (en) 2013-04-25
HK1135101A1 (en) 2010-05-28
JP6061897B2 (ja) 2017-01-18
PT2109602E (pt) 2014-05-23
JP2018039846A (ja) 2018-03-15
BRPI0720569B1 (pt) 2020-10-13
ES2463457T3 (es) 2014-05-28
EP2109602A2 (en) 2009-10-21
EP2452935A3 (en) 2012-08-29
JP2015205939A (ja) 2015-11-19
WO2008079339A2 (en) 2008-07-03
PL2109602T3 (pl) 2014-09-30
JP2021063137A (ja) 2021-04-22
BRPI0720569B8 (pt) 2021-05-25
US20160046561A1 (en) 2016-02-18
EP2109602B1 (en) 2014-02-12
SI2109602T1 (sl) 2014-06-30
US20100305072A1 (en) 2010-12-02
CA2673466A1 (en) 2008-07-03
CA3051994A1 (en) 2008-07-03
US8318706B2 (en) 2012-11-27
IL302749A (en) 2023-07-01
JP2019081802A (ja) 2019-05-30
CA2673466C (en) 2016-06-14
MX2009006846A (es) 2009-08-20
JP2011093914A (ja) 2011-05-12
WO2008079339A3 (en) 2008-12-18
EP3045449A1 (en) 2016-07-20
IL250858B (en) 2019-11-28
BRPI0720569A2 (pt) 2014-02-04
KR101538175B1 (ko) 2015-07-20
EP2450347A1 (en) 2012-05-09
EP2452935A2 (en) 2012-05-16
HK1170218A1 (en) 2013-02-22
ES2548261T3 (es) 2015-10-15
JP2010513527A (ja) 2010-04-30
EP3812372A2 (en) 2021-04-28
JP2024009235A (ja) 2024-01-19
EP2450347B1 (en) 2015-06-24
IL250858A0 (en) 2017-04-30
EP2455367B1 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
CA2925939C (en) Substituted tetracycline compounds
AU2004259659B2 (en) Substituted tetracycline compounds
JP2010513527A5 (enExample)
EP2301916A2 (en) 4-aminotetracyclines and methods of use thereof
US20250388531A1 (en) Substituted tetracycline compounds
CA2744317A1 (en) Substituted tetracycline compounds
HK1170218B (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
AU2012200575A1 (en) Substituted tetracycline compounds
AU2012216640A1 (en) 4-aminotetracyclines and methods of use thereof
HK1155386A (en) Substituted tetracycline compounds
HK1155385A (en) Substituted tetracycline compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161005